Trial Profile

A Phase 2 clinical study of NS002 intranasal epinephrine powder for the treatment of anaphylaxis

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 11 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Epinephrine (Primary)
Indications Anaphylaxis
Focus Adverse reactions; Therapeutic Use

Most Recent Events

20 Jan 2026 According to a Nasus Pharma media release,Full Phase 2 results are expected by the end of first quarter of 2026.
20 Jan 2026 Interim results presented in the Nasus Pharma media release.
20 Jan 2026 Status changed from planning to active, no longer recruiting, according to a Nasus Pharma media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com